Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

alexion pharma gmbh - selumetinibum - hartkapseln - selumetinibum 10 mg ut selumetinibi hydrogenosulfas, tocofersolanum, kapselhülle: hypromellosum, carrageenanum, kalii chloridum, e 171, aqua purificata, cera carnauba, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - neurofibromatose typ 1 (nf+) und plexiforme neurofibrome (pn) - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

alexion pharma gmbh - selumetinibum - hartkapseln - selumetinibum 25 mg ut selumetinibi hydrogenosulfas, tocofersolanum, kapselhülle: hypromellosum, carrageenanum, kalii chloridum, e 171, e 132, e 172 (flavum), aqua purificata, cera carnauba, maydis amylum, drucktinte: e 172 (rubrum), e 172 (flavum), e 132, cera carnauba, lacca, glyceroli mono-oleas, pro capsula. - neurofibromatose typ 1 (nf+) und plexiforme neurofibrome (pn) - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastische mittel - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Europäische Union - Deutsch - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopisch - andere dermatologische präparate - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - filmtabletten - abrocitinibum 50 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.814 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 1.365 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - filmtabletten - abrocitinibum 100 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.629 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 2.73 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva - sunitinib - hartkapsel - 12,5 mg - sunitinib 12.5 mg - sunitinib